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Jmjd6, a JmjC Dioxygenase with
Many Interaction Partners and
Pleiotropic Functions
Janice Kwok, Marie O’Shea, David A. Hume and Andreas Lengeling*
The Roslin Institute and Royal (Dick) School of Veterinary Studies, University of Edinburgh, Edinburgh, UK
Lysyl hydroxylation and arginyl demethylation are post-translational events that are
important for many cellular processes. The jumonji domain containing protein 6 (JMJD6)
has been reported to catalyze both lysyl hydroxylation and arginyl demethylation on
diverse protein substrates. It also interacts directly with RNA. This review summarizes
knowledge of JMJD6 functions that have emerged in the last 15 years and considers
how a single Jumonji C (JmjC) domain-containing enzyme can target so many different
substrates. New links and synergies between the three main proposed functions of
Jmjd6 in histone demethylation, promoter proximal pause release of polymerase II
and RNA splicing are discussed. The physiological context of the described molecular
functions is considered and recently described novel roles for JMJD6 in cancer and
immune biology are reviewed. The increased knowledge of JMJD6 functions has wider
implications for our general understanding of the JmjC protein family of which JMJD6 is
a member.
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INTRODUCTION
The jumonji domain-containing protein 6 (Jmjd6) is a member of the large family of JmjC
domain-containing metalloenzymes. These proteins are ferrous iron (Fe2+)- and 2-oxoglutarate
(2OG)-dependent dioxygenases that can catalyze hydroxylation and demethylation reactions on
protein and nucleic acid substrates (Hausinger, 2004; Loenarz and Schofield, 2008; Markolovic
et al., 2015; Martinez and Hausinger, 2015). The JmjC protein subfamily of histone demethylases
perform essential functions as regulators of transcriptional control, chromatin structure, epigenetic
inheritance, and genome integrity (Klose and Zhang, 2007; Pedersen and Helin, 2010; Kooistra and
Helin, 2012; Fedeles et al., 2015). Jmjd6 is one of the smallest JmjC proteins (Fadok et al., 2000;
Cikala et al., 2004; Tibrewal et al., 2007; Hahn et al., 2010) and appears to interact with multiple
protein substrates in distinct molecular pathways. Jmjd6 contributes to the regulation of histone
demethylation, transcriptional polymerase II promoter pause release and mRNA splicing (Chang
et al., 2007; Webby et al., 2009; Liu et al., 2013) through its ability to catalyze two types of reactions,
lysyl hydroxylation and N-methyl argininyl demethylation. The latter catalytic mechanism is
controversial but of particular importance because until recently Jmjd6 was proposed to be the only
enzyme capable of catalyzing arginine demethylation. Arginine methylation is quantitatively one of
the most extensive protein methylation reactions in mammalian cells (Bedford and Clarke, 2009).
Analysis of the human arginine methylome identified 8030 high-confidence monomethylarginine
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sites on 3300 proteins in human embryonic kidney (HEK) 293
cells (Larsen et al., 2016). Arginine monomethylation is only the
prerequisite for the enzymatic catalysis of arginine dimethylation,
so the vast number of differently arginine-methylated proteins
in cells suggests that this post-translational modification (PTM)
is as widespread as phosphorylation and ubiquitination (Clarke,
2013; Biggar and Li, 2015; Poulard et al., 2016; Blanc and
Richard, 2017). Since arginine methylation is a reversible and
dynamic PTM, an understanding of the underlying enzymatic
writer, reader and eraser systems for protein methylation has
become a key priority area of investigation (Bedford and Clarke,
2009; Carlson and Gozani, 2014; Sylvestersen et al., 2014).
The potential role of Jmjd6 in erasing arginine methylation is
therefore topical, if controversial (Mantri et al., 2010; Böttger
et al., 2015).
This review summarizes our current knowledge about Jmjd6
interaction partners, its identified catalytic substrates and
proposed molecular functions. We will discuss how a single
JmjC protein can target so many different substrates. We will
highlight studies from the past 15 years which have significantly
contributed to our current understanding of Jmjd6 functions
and identify new links and connections between the three main
proposed functions of Jmjd6 in transcriptional control that have,
as yet, not received much attention. This will cover the cross-talk
and synergy between histone demethylation, promoter-proximal
pause release of polymerase II and RNA splicing. Finally, we will
discuss Jmjd6 functions in a physiological context and review its
recently described novel roles in cancer and immune biology.
THE Jmjd6 PROTEIN – BASIC
STRUCTURAL FEATURES AND
POTENTIAL FUNCTIONS
Jmjd6 was discovered 17 years ago and named phosphatidylserine
receptor (PSR, Ptdsr) because it appeared to function as
a transmembrane receptor for recognition and clearance of
apoptotic cells (Fadok et al., 2000; Segawa and Nagata, 2015).
Subsequent studies in mice, Hydra and cell lines demonstrated
that the ‘PSR’ function was incorrectly assigned and that Jmjd6
is predominantly located in the cell nucleus (Böse et al., 2004;
Cikala et al., 2004; Cui et al., 2004; Mitchell et al., 2006; Wolf et al.,
2007). By cloning the homologous gene in Hydra, Cikala et al.
(2004) recognized that the protein sequence contains a central
jumonji C (JmjC) fold, and predicted that the protein would
function as Fe2+ and 2OG-dependent dioxygenase. Subsequent
confirmation of this activity (Chang et al., 2007; Webby et al.,
2009), led to the renaming of the protein as Jmjd6.
Jmjd6 is conserved from mammals to yeast (Hahn et al.,
2008). The central JmjC domain (residues 141 to 305, in human
JMJD6, UniProt ID Q6NYC1, Figure 1A) forms the typical
cupin or double-stranded β-helix fold (DSBH) shared by all
known 2OG-dependent dioxygenases (Clissold and Ponting,
2001; Loenarz and Schofield, 2008; Hong et al., 2010; Mantri
et al., 2010). The DSBH fold forms a barrel-like structure
with eight anti-parallel β-strands forming the major and minor
β-sheets in which the Fe2+ binding site of the catalytic center
is located at the open end of the barrel. The residues forming
this Fe2+ binding site (His187, Asp189, and His273) follow
the conserved HXD/E(Xn)H motif characteristic of JmjC family
members and are essential for the enzymatic activity of Jmjd6
as demonstrated by mutagenesis analyses (Chang et al., 2007;
Webby et al., 2009; Liu et al., 2013; Heim et al., 2014).
Two protein crystal structures have been reported for Jmjd6
(Hong et al., 2010; Mantri et al., 2011). The first structure was
obtained from a truncated Jmjd6 protein lacking the C-terminal
located poly serine rich region (polyS, residues 340–365 in
Q6NYC1) which was reported to be incompatible with crystal
formation (Mantri et al., 2010). Interestingly, this structure
shows Jmjd6 crystallized as a homo-dimer and reveals details
about the interfacing β-strands and α-helixes that are involved
in dimer formation. Two α-helixes positioned at the N- and
C-terminal ends of the protein (residues 61–68 and 322–334
in human JMJD6) are essential for Jmjd6 homo-dimerization
(Mantri et al., 2010; Wolf et al., 2013). Homo-oligomerization
of JmjC domain-containing proteins has also been reported for
other family members. For example, the factor inhibiting HIF
(FIH), which is structurally similar to Jmjd6, spontaneously
forms dimers in solution. Other examples include the tRNA
hydroxylase, TYW5, and the ribosomal oxygenase 1 (RIOX1,
also known as NO66), which can oligomerise to form dimers
or tetramers, respectively (Kato et al., 2011; Tao et al., 2013).
Jmjd6 can also form trimers, tetramers, and pentamers by
homo-multimerization (Hahn et al., 2010; Han et al., 2012;
Wolf et al., 2013). The formation of these multimers has
been proposed to require the catalytic activity of Jmjd6 (Han
et al., 2012). Like other JmjC hydroxylases, the protein is
capable of carrying out autohydroxylations (Mantri et al., 2012)
which may be necessary for the intermolecular cross-linking
of Jmjd6 monomers (Han et al., 2012). As a consequence
these multimers are partially resistant to sodium dodecyl sulfate
treatment and are visible as discrete protein fragments on
western blots (Tibrewal et al., 2007; Hahn et al., 2010; Wolf
et al., 2013). Importantly, the expression of these multimers
varies in different cell types, which may confuse analysis of the
specificity of Jmjd6 antibodies in protein immunoprecipitation
or western blot analysis. Since the discovery of Jmjd6 the
whole field has been misled by cross-reactivity of anti-Jmjd6
antibodies (Fadok et al., 2000; Böse et al., 2004; Wolf et al.,
2007; Böttger et al., 2015). Many commercially available anti-
Jmjd6 antibodies recognize unknown fragments above the 50 kD
monomer fragment in Jmjd6 knockout cells (Hahn et al., 2010).
Therefore, new anti-Jmjd6 antibodies must be validated using
Jmjd6-deficient cells. The cellular function of the different Jmjd6
multimers is unknown. They may be formed under different
physiological conditions in different nuclear compartments.
Electron microscopy studies performed with recombinant Jmjd6
protein have suggested that monomers polymerize into ring-
like structures (Wolf et al., 2013). The formation of these
structures in vivo and the question of whether they are
part of larger protein scaffolds or complexes requires further
investigation.
Besides its catalytic JmjC domain, Jmjd6 has a poly-
serine (polyS) stretch domain at its C-terminus (residues
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FIGURE 1 | Protein domains and motifs of Jmjd6. (A) Schematic presentation of the full-length JMJD6 protein (403 amino acids, UniProt ID Q6NYC1) with
central JmjC domain (green), nuclear localization sites (NLS, blue), nuclear export signal (NES, red), predicted SUMOylation site (light blue), and C-terminal poly
serine (pink). Fe2+ complexing residues are shown as purple balls (His187, Asp189, His273). Scale indicates the length of the 403 amino acid (aa) comprising protein
(B) Sequence of an extended AT-hook-like motif in JMJD6. Shown on the top line is the consensus sequence of an extended AT hook (eAT) after (Filarsky et al.,
2015). GRP indicates the glutamine-arginine-proline tripeptide core motif which is surrounded in close proximity by at least three basic leucine (L) and/or arginine (R)
residues. X indicates any amino acid in a distance of 6–20 amino acids from the GRP core motif. Bottom line: peptide eAT-hook-like sequence of JMJD6 (residues
283–326). GRP core motif is depicted in blue, basic K and R amino acids in red. The central/canonical AT-hook sequence is underlined. Note that the JMJD6
eAT-hook sequence with basic amino acids (K/R) is only extended distally to the GRP core motif sequence. Thus, Jmjd6 appears to have a hybrid AT hook sequence
motif as discussed in the text (see The Jmjd6 Protein – Basic Structural Features and Potential Functions).
340–365 in Q6NYC1, Figure 1A). This domain is missing in
alternatively spliced variants of Jmjd6 which are likely to have
distinct biological functions (Hahn et al., 2008; Wolf et al.,
2013). The polyS domain is important for the subnuclear
localization of Jmjd6 (Wolf et al., 2013); in its absence Jmjd6
variants are predominantly localized in the fibrillar center
of the nucleolus. In immunoprecipitation experiments, Jmjd6
without the polyS domain interacts with nucleolar proteins
(Wolf et al., 2013), suggesting a function for the domain in
nuclear/nucleolar shuttling of the protein. We have observed
different amounts of nucleolar and nucleoplasmatic Jmjd6 in
individual cells in culture (Hahn et al., 2010). Whether these
different Jmjd6 nuclear expression patterns are dependent on
the cell cycle or on other physiological stimuli needs to be
determined.
Jmjd6 has five predicted nuclear localization sites (NLSs) and
one nuclear export signal (NES) (Figure 1A). Two of the NLS
overlap the JmjC domain and may not be topologically accessible
in vivo (Cikala et al., 2004; Cui et al., 2004). Three NLS have been
validated using Jmjd6 reporter deletion constructs (Cikala et al.,
2004). Other sequence motif predictions in Jmjd6 which still
demand experimental validation are a putative sumoylation site
(K317 in Q6NYC1, Hahn et al., 2010) and an AT-hook domain
(residues 299–317 in Q6NYC1, Cikala et al., 2004) which has been
originally described as a DNA binding motif in the high mobility
group AT-hook 1 protein (HMGA1) (Reeves and Nissen, 1990).
The AT-hook in HMGA1 facilitates protein binding to the minor
groove of DNA (Huth et al., 1997). There is no evidence that
Jmjd6 binds to DNA (Hong et al., 2010), but it does interact
with RNA. The nuclear staining pattern of Jmjd6 is lost
in RNase A treated cells (Hahn et al., 2010) and specific
interactions of Jmjd6 with arginine-serine-rich (RS)-domain
containing proteins were found to be mediated at least partially
through interaction with RNA (Heim et al., 2014). Jmjd6
associates with nascent RNAs in the nucleoplasm, identified as
distinct dots by labeling RNA in HeLa cells with 5-fluorouridine
(Heim et al., 2014). In the report describing the monomeric
crystal structure of Jmjd6, the full-length protein was shown
to bind without sequence specificity to random RNA oligos
of 21–27 nucleotide length (Hong et al., 2010). Additional
evidence of RNA binding to Jmjd6 has been obtained in co-
precipitation studies which have analyzed the association of
Jmjd6 with mRNA or small nuclear (sn) RNA in relation
to its involvement in splicing and transcriptional pausing as
discussed below (Boeckel et al., 2011; Liu et al., 2013; Heim
et al., 2014). One candidate binding motif identified within
Jmjd6 is a variation of the original AT-hook motif (Filarsky
et al., 2015). It contains the glycine-arginine-proline (GRP) core
motif of the canonical AT-hook but is extended symmetrically
in both directions with basic amino acids at a distance of
12–15 residues. The extended AT-hook peptide motif (eAT-
hook) was shown to have a higher affinity for RNA than DNA
(Filarsky et al., 2015). However, the Jmjd6 AT-hook sequence
contains neither a canonical AT-hook nor an eAT-hook motif
(Figure 1B). The GRP core in Jmjd6 is extended with basic
lysine and arginine residues in the C-terminal direction from
the core but not in the N-terminal direction as described
for eAT-hooks (Figure 1B). Thus, Jmjd6 possess a hybrid
between a canonical and an extended AT-hook. Whether this
peptide motif is directly involved in mediating interactions of
Jmjd6 with RNA needs to be investigated using mutagenesis
studies.
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Many different substrates of Jmjd6 have been reported in
the literature, with different levels of evidence (Supplementary
Table S1). Some studies have provided indirect evidence
that Jmjd6 catalyzes demethylation of arginine residues in target
proteins using methylation-specific antibodies in immunopre-
cipitation and/or western blot analyses (Supplementary
Table S1). Others describe in vitro assays with recombinant
Jmjd6 protein purified from Escherichia coli and peptides
derived from candidate protein substrates (Chang et al., 2007;
Webby et al., 2009; Webby, 2012; Liu et al., 2013; Unoki
et al., 2013; Wang et al., 2014; Gao et al., 2015). To provide
definitive evidence for genuine Jmjd6 catalyzed reactions,
matrix-assisted laser desorption/ionization (MALDI) mass
spectrometry (MS) analyses are required to demonstrate
reaction products derived from endogenous proteins. Such
in vivo evidence has been provided in only three studies. Using
liquid chromatography–mass spectrometry/mass spectrometry
(LC–MS/MS) analyses Webby et al. (2009) demonstrated
that the splicing factor U2 small nuclear ribonucleoprotein
auxiliary factor 65-kilodalton subunit (U2AF65) from HeLa
cells is lysyl-5-hydroxylated by Jmjd6 at positions K15 and
K276. Overexpression of Jmjd6 in HeLa cells resulted in
a 5-fold increase in hydroxylation of U2AF65 at K15 thus
providing further evidence that U2AF65 is a genuine Jmjd6
substrate in vivo (Webby et al., 2009). Similarly, MS analyses
indicated that immunoprecipitated Jmjd6 undergoes self-
hydroxylation on K167 in HeLa cells (Webby, 2012) and
JMJD6 lysyl-hydroxylates endogenous p53 on position K382
in HCT116 colon cancer cells (Wang et al., 2014) (as discussed
below).
The evidence that the protein is also catalyzing N-methyl-
arginine demethylation reactions is less compelling. The
proposed arginine demethylation activity of Jmjd6 has been
suggested to involve an initial hydroxylation reaction on
the N-methyl group which yields an unstable hemiaminal
intermediate that subsequently fragments into the demethylated
arginine residue and formaldehyde as a by-product (Chang
et al., 2007; Loenarz and Schofield, 2008; Böttger et al., 2015).
Comparison of available structures from JmjC hydroxylases
and JmjC histone lysine demethylases (KDMs) with that of
Jmjd6 suggests that N-methyl-arginine groups might not easily
penetrate into the catalytic cavity site of Jmjd6 [for excellent
reviews on JmjC protein structure comparisons see (Loenarz
and Schofield, 2011; Böttger et al., 2015; Markolovic et al., 2015,
2016)]. Other JmjC proteins can undergo large conformational
changes to accommodate different substrates (Scotti et al.,
2014). Nevertheless, direct evidence for the proposed N-arginine
demethylation activity of Jmjd6 remains to be established
using endogenous protein substrates and employing either
detailed MS-fragmentation studies and/or NMR amino acid
analyses.
In conclusion, Jmjd6 is a relatively small JmjC domain
containing protein that interacts with RNA and has an enzymatic
function as Fe2+- and 2OG-dependent dioxygenase. Its nuclear
function as lysyl-hydroxylase has been validated on endogenous
substrates in different cells but its possible function as an arginine
demethylase still awaits experimental validation in vivo.
EXPRESSION OF Jmjd6 IN VIVO AND
PHENOTYPES REPORTED IN
Jmjd6-DEFICIENT OR
Jmjd6-OVEREXPRESSING MODEL
ORGANISMS
Jmjd6 is expressed during all stages of mouse development.
Specific patterns of expression can be detected at embryonic
stages E9.5-12.5 in the developing neural tube, somites, heart,
gut, limb buds and eyes (Böse et al., 2004; Schneider et al.,
2004). In adult mice Jmjd6 is ubiquitously expressed in most
tissues at a moderate or low level. More prominent expression
can be found in testis, thymus, heart, kidney, liver and skin
(Böse et al., 2004). The BioGPS portal which provides public
access to the Gene Atlas Affymetrix array sets from 61 mouse
and 79 human tissues, organs, and cell lines shows in general
a good correlation of Jmjd6/JMJD6 expression between both
species (Supplementary Figure S1; Wu et al., 2009). Jmjd6 is
expressed throughout the hematopoietic system with significant
expression levels in progenitor stem cells of the myeloid and
lymphoid lineages. Strong expression levels of Jmjd6/JMJD6
can be found in CD4+ and CD8+ T cells, B cells, NK cells
and monocytes (Supplementary Figure S1). This pattern of
expression is confirmed in the extensive promoter-based gene
expression analysis from the FANTOM Consortium and the
RIKEN PMI and CLST (DGT) et al. (2014) where the highest
expression of Jmjd6 was observed in myeloid cells (granulocytes,
mast cells, and monocytes).
Loss-of-functions studies in knockout mice have
demonstrated that Jmjd6 has essential functions in
embryogenesis and tissue differentiation. Jmjd6 knockout
mice die neonatally at the latest (Li et al., 2003; Böse et al.,
2004; Kunisaki et al., 2004). In our knockout strain, which
was generated on a C57BL/6J genetic background (Böse et al.,
2004), we have observed a low rate of embryonic lethality in
utero (5–6%). Jmjd6 knockout mice display a range of defects
during embryogenesis. From midgestation onward delays in
the differentiation of lungs, kidneys, the intestine, the thymus
and eyes can be observed (Böse et al., 2004; Kunisaki et al.,
2004). Brain development is severely affected with sometimes
extensive hyperplasia of brain tissue that leads to exencephaly
(Li et al., 2003; Böse et al., 2004). Homozygous knockout mice
with severe head and craniofacial malformations are often
also anophthalmic with uni- or bilateral absence of eyes (Böse
et al., 2004). Erythropoiesis in the fetal liver is blocked at
an early erythroblast stage (Böse et al., 2004; Kunisaki et al.,
2004). Jmjd6−/− mice also show drastic defects in thymocyte
differentiation. At embryonic day E18.5 around only 15% of
double positive CD4+ and CD8+ T cells are found in thymus
of Jmjd6−/− mice in comparison to wild-type littermates,
demonstrating early defects in T-lymphopoiesis (Kunisaki
et al., 2004). The function of Jmjd6 in thymus development
has been analyzed using fetal thymus grafts of wild-type and
Jmjd6−/− embryos into the renal capsules of athymic nude mice
(Yanagihara et al., 2015). The expression of the autoimmune
regulator protein, Aire, was ablated in medullary thymic
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epithelial cells (mTEC) of Jmjd6 knockout grafts. Aire is a
transcriptional regulator protein that induces expression of
peripheral tissue self-antigens in the thymus (Peterson et al.,
2008), thereby controlling negative selection of self-reactive
thymocytes and promoting immunological tolerance. Ablation
of Aire function prevents deletion of autoreactive T cells and
causes multiorgan autoimmune disorders (Chan and Anderson,
2015). Jmjd6 appears to control Aire expression in mTECs by
regulating the splicing of Aire transcripts (Yanagihara et al.,
2015). In the absence of Jmjd6, intron 2 of the Aire transcript
was not effectively spliced out resulting in the generation of
a premature stop codon and expression of a truncated and
unstable protein. The lack of functional Aire protein expression
in Jmjd6−/− mTECs generates multi-organ autoimmunity in
nude mice that are reconstituted with thymic Jmjd6 knockout
grafts (Yanagihara et al., 2015). Whether the mis-splicing of Aire
transcripts involves a failure in Jmjd6 mediated hydroxylation of
splicing regulatory proteins remains unknown but is one likely
molecular explanation of the observed defect (see below).
Neonatal Jmjd6 knockout mice die from severe
cardiopulmonary malformations involving ventricular septal
defects, a double outlet right ventricle, and pulmonary artery
hypoplasia (Schneider et al., 2004). Controversy exists over
the function of Jmjd6 in apoptotic cell clearance. Two of the
reported Jmjd6 knockout mice are in fact double mutant mice
(Li et al., 2003; Kunisaki et al., 2004) which lack, in addition to
Jmjd6, the neighboring gene methyltransferase like 23 (Mettl23)
(Hahn et al., 2008). Mettl23 encodes a predicted S-adenosyl-
methionine-dependent methyltransferase and its locus overlaps
with Jmjd6 (Hahn et al., 2008). Both genes are oriented in a head-
to-head transcriptional orientation and transcriptional start sites
(TSS) for Jmjd6 and Mettl23 are in close proximity (Figure 2).
Jmjd6 and Mettl23 cluster in a ‘head-to-head’ transcriptional
orientation in all vertebrates from humans to puffer fish (Hahn
et al., 2008). Such ancestral conservation of head-to-head gene
organization is often correlated with significant overlap of
expression patterns and functional associations of the genes
involved (Li et al., 2006; Gherman et al., 2009). Although the
precise TSS do not overlap, both genes are widely expressed in
mouse and human datasets in FANTOM5, and the two genes
probably share transcriptional regulatory elements within the
CpG island that overlaps the shared TSS region. Nevertheless,
in humans their expression is divergent in that METTL23 is
not over-expressed in myeloid cells, and conversely, is high
in T cells. Loss-of-function mutations in human METTL23
have been reported to cause mild non-syndromic or severe
syndromic autosomal recessive intellectual disability (ARID).
Two truncating mutations in METTL23 in unrelated Austrian
and Pakistan families disrupt the predicted catalytic domain
of METTL23 and alter the cellular localization of the protein
(Bernkopf et al., 2014). Another loss-of-function mutation in the
5′-region of METTL23 has been described which is associated
with ARID and craniofacial abnormalities in a family of Arabian
origin (Reiff et al., 2014). This four base pair deletion affects the
coding region of three METTL23 transcripts and the 5′-UTR of
another three alternative transcripts. It is not known whether this
5′ located mutation also effects JMJD6 expression. The reported
craniofacial phenotypes in the Arabian family, which includes
a cleft palate, are similar to craniofacial dysmorphologies that
are observed in Jmjd6 knockout mice (Böse et al., 2004; Reiff
et al., 2014). The conserved shared regulation of JMJD6 and
METTL23 suggests that they might target some substrates in
common and could therefore act in shared pathways perhaps
as corresponding writer and eraser enzymes. If such is the case,
the cell-type specific roles could be impacted by changes in their
relative expression.
Essential roles for Jmjd6 in tissue differentiation and
embryogenesis have also been demonstrated in zebrafish.
A morpholino knockdown of zebrafish jmjd6 caused severe
delays in organogenesis and early lethality with failures to hatch
from the egg (Hong et al., 2004). The observed phenotypes
correlate with those found in the mouse knockout lines
including severe morphological defects in the developing brain,
heart, notochord and somites. Increased numbers of apoptotic
cells were reported in jmjd6 morpholino injected embryos in
comparison to controls (Hong et al., 2004), but these results do
not distinguish whether the underlying cause is an increase in cell
death or a failure of clearance.
In Drosophila, genetic ablation of dJMJD6 expression
produced no obvious phenotypes and homozygous knockout
flies are viable and fertile (Krieser et al., 2007). Overexpression
of jmjd6 under ubiquitous promoters resulted in a rotated
male genital phenotype similar to fly mutants lacking the
developmental apoptosis regulator head involution defective
(hid) (Krieser et al., 2007). Co-expression of jmjd6 and hid
in the developing Drosophila eye suppressed a small rough
eye phenotype that can be induced by overexpression of hid
alone. These observations led to the hypothesis that dJMJD6
suppresses Hid-dependent apoptosis during the pupal phase of
eye development and possibly also in other fly tissues during
embryogenesis (Krieser et al., 2007). In Caenorhabditis elegans
the loss of jmjd6 has been reported to be associated with
mild apoptotic cell engulfment defects (Wang et al., 2003)
although this is controversial (Arur et al., 2003). A defect in
regenerative axon fusion has been described in jmjd6 deficient
C. elegans mutants after laser ablation of mechanosensory
neurons (Neumann et al., 2015). However, other worms that lack
jmjd6 have no obvious phenotypes. Together with the genetic
studies in Drosophila this shows that jmjd6 is not essential
for embryogenesis and development in invertebrates and by
inference, the gene has acquired new, non-redundant functions
in the vertebrate lineage.
BIOLOGICAL FUNCTIONS OF Jmjd6 IN
TRANSCRIPTIONAL CONTROL
The discovery of an enzymatic function of Jmjd6 as 2OG-
dependent dioxygenase suggested that the protein plays a role
in the epigenetic regulation of chromatin structure and gene
expression (Chang et al., 2007). Jmjd6 catalyzes demethylation
of dimethylated arginine residues at histone H3 arginine 2
(H3R2me2) and histone H4 arginine 3 (H4R3me2). These
findings suggested for the first time that arginine residues
Frontiers in Genetics | www.frontiersin.org 5 March 2017 | Volume 8 | Article 32
fgene-08-00032 March 14, 2017 Time: 15:37 # 6
Kwok et al. New Functional Insights into Jmjd6
FIGURE 2 | FANTOM5 analysis of the human locus encompassing the JMJD6 and METTL23 loci. FANTOM5 CAGE sequence data as depicted in the
Zenbu browser and described by the (FANTOM Consortium and the RIKEN PMI and CLST (DGT) et al., 2014). Top line: shown are the Entrez hg 19 JMJD6 (purple
arrow) and METTL23 (green arrow) transcriptional orientations. Sequence positions on human chromosome 17 are indicated on the top. Gencode v19 transcripts for
JMJD6 (purple) and METTL23 (green) are shown below. Rectangles indicate exons and lines introns. Note: at the proximal and distal borders of the depicted JMJD6
and METTL23 loci the Zenbu browser screen view shows parts of the neighboring genes MXRA7 and SRSF2 in this gene dense genomic region. FANTOM5 CAGE
and ENCODE CAGE sequence peaks are shown in the center. JMJD6 CAGE sequence peaks are shown in purple, METTL23 CAGE sequence peaks in green.
Bottom graph: relative transcriptional start site (TSS/CAGE) expression data for JMJD6 (purple) and METLL23 (green) in blood cells from different donors. Relative
TTS tag incidence refers to CAGE sequence tag counts across the locus which are quantified as normalized tags per million (TPM) as previously described (FANTOM
Consortium and the RIKEN PMI and CLST (DGT) et al., 2014). CAGE sequence peaks for both genes are partially overlapping in eosinophils, neutrophils, and natural
killer cells. The data shown are from the FANTOM5 database publically accessible at the Zenbu browser (http://fantom.gsc.riken.jp/5/) when searching for JMJD6 or
METTL23.
in histones might be reversibly methylated and demethylated
and identified Jmjd6 as the long sought-after eraser enzyme
for these regulatory histone marks. All other identified JmjC
domain containing histone demethylases target lysine residues
in the tails of histone H3 and H4 (H3K4, H3K9, H3K27,
H3K36 and H4K20, Greer and Shi, 2012; Kooistra and Helin,
2012) and have been accordingly named lysine demethylases
(KDMs) (Allis et al., 2007). The large KDM subfamily of JmjC
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dioxygenases is grouped based on sequence homology into
subfamilies KDM1 to KDM6. The histone lysine residues can be
mono-, di-, or trimethylated and are linked to transcriptional
activation (H3K4, H3K36, H3K79) or transcriptional inhibition
(H3K9 and H3K27) based on their location on promoters
and enhancers (for review see, Zhou et al., 2011). Histone
arginine residues can be monomethylated or symmetrically
or asymmetrically dimethylated depending on the position of
one or two methyl groups on the guanidino group of the
arginine (Figure 3). Asymmetric dimethylation of H3R2me2a
associates with transcriptional repression (Guccione et al.,
2007; Hyllus et al., 2007) whereas symmetric dimethylation
or monomethylation of H3R2 (H3R2me2s and H3R2me1,
respectively) associates with gene activation (Migliori et al.,
2012; Yuan et al., 2012). Asymmetric dimethylation methylation
of histone 4 at arginine 3 (H4R3me2a) can facilitate p300-
mediated acetylation of H3 and H4 at different lysine residues
and can thereby promote transcriptional activation (Wang et al.,
2001; Li et al., 2010). In contrast, symmetrically dimethylated
H4R3me2s strongly inhibits downstream methylations of H3K4
and has thereby been implicated in transcriptional repression
(Zhao et al., 2009). Initial evidence for Jmjd6 acting as a
histone arginine demethylase (Chang et al., 2007) was based
upon incubating recombinant JMJD6 protein with purified
bulk histones and synthetic histone tail peptides with various
methylated lysine and arginine sites and demonstrated reductions
in H3R2me2 and H4R3me2 methylation levels. These were
detected using western blots with histone methylation specific
antibodies that did not differentiate between symmetrically
and/or asymmetrically dimethylated arginine residues (Chang
et al., 2007). A recombinant JMJD6 protein with mutations
of the Fe2+ binding residues in the JmjC domain did not
demethylate H3R2me2 and H4R3me2 peptides. The results were
corroborated using MALDI-TOF mass spectrometry. However,
detection of the expected mass shifts on the synthetic H3R2me2
and H4R3me2 histone peptides required enrichment of the
H3R2me1 and H4R3me1 reaction products with monomethyl-
specific antibodies which suggests relatively weak activity. Finally,
over-expression of wild-type, but not inactive JMJD6 protein
in HeLa cells, produced global reduction of H3R2me2 and
H4R3me2 levels in transfected HeLa cells (Chang et al., 2007).
Others have not reproduced Jmjd6 arginine demethylation
activity when using H3 and H4 histone peptides in MS-based
assays (Webby et al., 2009; Han et al., 2012; Unoki et al.,
2013).
A more consistent finding is that JMJD6 can lysyl-hydroxylate
histone peptides in vitro with no apparent sequence specificity.
Comparative amino acid component analysis of purified histones
from wild-type and Jmjd6 knockout mice, revealed differences
in monohydroxylation of multiple lysine residues in the tails
of histone H3 and H4 (Unoki et al., 2013). This lysyl-5-
hydroxylation activity of Jmjd6 on histones was evident in mouse
testis, embryos and ES cells suggesting that this new type of
histone PTM might be physiologically relevant. 5-hydroxylation
of lysyl residues can inhibit subsequent acetylation and
methylation at the same site (Unoki et al., 2013) suggesting
a role in chromatin configuration and epigenetic regulation
of gene expression. Whether Jmjd6 has a role in mediating
such histone cross-talk modifications in vivo needs to be tested.
This will require a genome wide profiling of both active and
repressive histone lysine modification marks with ChIP-seq in
Jmjd6 wild-type and deficient cells to determine whether such
regulation might occur locally on chromatin. Global assays
for alterations of histone lysine methylation marks in Jmjd6-
overexpressing and Jmjd6-deficient cells have so far failed to
provide evidence for a function of Jmjd6 as a KDM (Hahn et al.,
2010).
Jmjd6 might locally demethylate H4R3me2s at certain loci
and therefore be associated with transcriptional activation. Jmjd6
appears to act as a regulator of DNA polymerase II (Pol II)
promoter-proximal pause release (Liu et al., 2013). Promoter-
proximal pausing of Pol II is a sophisticated mechanism
in metazoans which regulates the timing and magnitude of
transcriptional responses (for review see, Adelman and Lis,
2012; Jonkers and Lis, 2015). After recruitment of Pol II to
gene promoters and initial transcription of an mRNA of 20–60
nucleotides in length, Pol II often pauses until additional signals
promote productive elongation of the nascent mRNA. Promoter-
proximal pause release of Pol II is a major mechanism of
transcriptional regulation in response to extracellular stress
signals (e.g., heat shock, hypoxia, inflammation) and activation of
genes in response to differentiation signals during embryogenesis
and development (Liu et al., 2015). In this context, Jmjd6
interacts with the bromodomain-containing protein 4 (Brd4)
and components of the positive transcription elongation factor
b (P-TEFb) complex, a heterodimer consisting of the cyclin-
dependent kinase Cdk9 and a cyclin component (cyclin T1,
T2a/b, or K) (Liu et al., 2013). P-TEFb phosphorylates Pol
II at serine 2 (Ser2-P) in the C-terminal (CTD) heptapeptide
repeat region of the polymerase as well as the negative
elongation factor (NELF) which forms a complex with the
DRB sensitivity-inducing factor (DSIF) and Pol II, thereby
blocking early transcriptional elongation. Brd4 binds to the
cyclin T component of P-TEFb and thereby frees P-TEFb
from a sequestered inactive ribonucleoprotein complex which
contains the small nuclear RNA 7SK (7SK snRNA), the
protein HEXIM 1 and the inactive P-TEFb heterodimer
(Figure 4).
Interactions of Jmjd6 with Brd4 had been reported previously
(Webby et al., 2009; Rahman et al., 2011) but the functional
consequences of this interaction were unclear. Jmjd6 and Brd4
bind together at distal enhancer regions of a large group of
genes called anti-pause enhancers (A-PEs) (Liu et al., 2013).
Recruitment of Jmjd6 to A-PEs by Brd4 induced demethylation
of the repressive H4R3me2s histone mark. The demethylation
activity was also directed at the 7SK snRNA which was shown
to serve as a reader of H4R3me2s histone marks. Demethylation
of the 5′-methyl cap of the 7SK snRNA was hypothesized to
lead to the activation of the P-TEFb complex. Taken together,
the data led to a model whereby Jmjd6 demethylation of the
5′-methyl cap induced degradation of the 7SK snRNA leading
to dissociation of the 7SK snRNA/HEXIM1 inhibitory complex
and retaining of active P-TEFb by Jmjd6 and Brd4 at Pol II pause
release promoters (Figure 4). Chromosome confirmation capture
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FIGURE 3 | Function of JMJD6 as a histone arginine demethylase. JMJD6 has been proposed to demethylate residues at histone H4 arginine 3 (H4R3) and
histone H3 arginine 2 (H3R2). Arginine residues can be symmetrically (SDMA) or asymmetrically (ADMA) dimethylated. 2-oxoglutarate- (2OG) and oxygen
(O2)-dependent demethylation of H4R3me2s and H3R2me2a by JMJD6 produces succinate, CO2, formaldehyde and monomethylated arginine residues. Both
arginine histone marks, H4R3me2s and H3R2me2a are associated with transcriptionally inactive chromatin. Demethylation by JMJD6 to the monomethyl arginine
(MMA) H4R3me1 or H3R2me1 histone marks is proposed to be associated with transcriptional activation.
analysis confirmed a long-range folding of A-PEs to the Pol II
paused promoters. Subsequent phosphorylation of Pol II on Ser2-
P by released P-TEFb leads to Pol II proximal promoter release
and gene activation (Liu et al., 2013, 2015).
Evidence for the catalytic function of Jmjd6 as a H4R3me2s
demethylase was provided in vitro by incubation of bacterial
recombinant or Flag-tagged HEK-293 cell purified Jmjd6 with
bulk histones and histone tail derived peptides using histone
methylation-specific antibodies and MALDI-TOF MS assays.
Importantly, knockdown of JMJD6 in HEK-293 cells produced
selective enrichment of H4R3me2s on Brd4 and Jmjd6 co-bound
distal enhancers. Jmjd6 mediated demethylation of the 5′-methyl
cap of the 7SK snRNA was shown using a dot blot in vitro
assay with immobilized methylated 7SK snRNA. Knockdown
of Jmjd6 or Brd4 in vivo increased 7SK snRNA occupancy
at distal A-PEs of Jmjd6 and Brd4 specifically at co-regulated
genes. The 7SK complex is part of megadalton sized promoter
complex which tethers Pol II to genomic DNA near promoter-
proximal regions. Serine–arginine (SR) rich proteins have been
shown to bind to these complexes and to function in Pol II
proximal promoter release. The SR protein SRSF2 (also known
as splicing factor SC35) interacts with the 7SK complex at gene
promoters and mediates release of P-TEFb in an RNA-dependent
manner thereby facilitating Pol II proximal promoter release
and transcriptional activation (Ji et al., 2013). In this context,
Jmjd6 protein interaction screens identify several SR- and SR-
like proteins, including SRSF2/SC35, among others, as binding
partners (Webby et al., 2009; Rahman et al., 2011; Heim et al.,
2014) (also see Discussion below on the role of Jmjd6 as a
splicing regulatory protein). Accordingly, Jmjd6 could have a
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FIGURE 4 | JMJD6 as a regulator of RNA polymerase II promoter-proximal pause release. Mechanistic model after Liu et al. (2013) on how JMJD6 regulates
transcriptional pause release through dual demethylation activity on H4R3me2s and the 7SK snRNA via interaction with BRD4 on anti-pause enhancers.
Demethylation of the 5′-methyl cap of the 7SK snRNA by JMJD6 leads to the dissociation of the positive transcription elongation factor-b (P-TEFb) complex from the
HEXIM1/2 polymerase II (Pol II) inhibitory complex. The P-TEFb complex (circled with a dashed green line) consists of the subunit proteins cyclin-dependent kinase 9
(CDK9) and cyclin T1/2 (CCNT1/2). Released P-TEFb phosphorylates serine 2 (Ser2-P) in the C-terminal heptapeptide repeat region of RNA-polymerase II (Pol II) and
the negative elongation factor (NELF) which causes its dissociation from the DRB sensitivity-inducing factor (DSIF). Both phosphorylation events facilitate release of
paused Pol II and efficient mRNA elongation. In the process of Pol II promoter-proximal pause release recruited JMD6 also demethylates H4R3me2s. Genomic DNA
with nucleosome and anti-pause enhancer depicted as gray line; mRNA (yellow line); 7SK snRNA (blue line); BRD4, bromodomain-containing protein 4 (purple);
DSIF, DRB sensitivity-inducing factor (blue); JMJD6, Jumonji domain containing protein 6 (red); Pol II, RNA-polymerase II (dark green); NELF, negative elongation
factor (orange); P-TEFb subunits CDK9, cyclin-dependent kinase 9 (light green) and CCNT1/2, cyclin T1/2 (light green); HEXIM 1/2 dimer, hexamethylene
bisacetamide inducible proteins 1 and 2 (violet); Ser2-P, phosphorylated serine 2 of Pol II and TSS, transcription start site; red lines indicating Jmjd6 mediated
demethylation reactions.
more general role in the coupling of processes that coordinate
mRNA transcription, splicing and 3′-mRNA processing. In a
follow up study that extended the discovery of Jmjd6 and
Brd4 mediated control of transcriptional Pol II, heat shock
protein 70 (HSP70) was found to be required for transcriptional
regulation of retinoid acid (RA) induced receptor β2 (RARB2)
gene activation by interacting with chromatin and components
of the transcription pre-initiation complex (Gao et al., 2015). The
monomethylation of a highly conserved arginine residue (R469)
in HSP70 was critical for HSP70 mediated recruitment of the
transcription factor TFIIH to the pre-initiation complex. Jmjd6
functions as a demethylase of R469me1 thus acting in this context
as a likely repressor of RA-induced gene activation (Gao et al.,
2015). The lack of significant global increases in HSP70 R469me1
levels upon knockdown of Jmjd6 in RA-stimulated cells suggests
that this demethylation function of Jmjd6 acts again very locally
and is context dependent (Gao et al., 2015). Therefore, it might
not be a major catalytic activity of Jmjd6 and the regulation
of the methylation status of HSP70 and its impact on Pol II
transcriptional activity warrants further investigation.
Taken together, functions of Jmjd6 in transcriptional/
epigenetic regulation of gene expression have solidified in recent
years. However, the question of which are the most biological
important functions of Jmjd6 in regulating promoter proximal
pause release of Pol II and/or histone modification (arginine
demethylation and/or histone hydroxylation) still needs further
clarification. This requires careful analysis of Pol II pause release
and simultaneous profiling of histone marks in a genome wide
context under physiological defined stimuli, preferentially in
primary cells and not in immortalized (tumorigenic) cell lines.
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FUNCTIONS OF Jmjd6 IN RNA
PROCESSING – REGULATION OF
SPLICING
Proteome interaction screens which have used transient expres-
sion of Jmjd6-epitope or Jmjd6-GFP tagged fusion proteins
coupled with affinity purification and mass spectrometry (LC–
MS/MS) have identified 35 Jmjd6 interacting proteins in at
least three out of four independent interaction screens in the
human HeLa and HEK-293T cell lines (Heim et al., 2014). The
majority of Jmjd6 candidate interactors (63%) were proteins
with functional GO annotations in RNA metabolism, RNA
processing, and RNA splicing; 16 are arginine-serine-rich (RS)
proteins of which nine are known components of the pre-
spliceosomal complex A (Heim et al., 2014). Two of the RS-
domain containing proteins, U2AF65 and the LUC7-like 2
pre-mRNA splicing factor (Luc7L2) were shown to be lysyl-5-
hydroxylated by Jmjd6 (Webby et al., 2009), U2AF65 at lysine
residues K15 and K276 and Luc7L2 at K266 and K269 (Webby
et al., 2009). The splicing of pre-mRNA is catalyzed by five small
nuclear ribonucleoprotein particles (snRNPs U1, U2, U4, U5,
and U6) and 100s of accessory proteins that together constitute
the spliceosome. The spliceosome complex starts to assemble by
recognizing the 5′-exon donor splice site, the intronic branch
point and polypyrimidine (PY)-tract and the 3′-exon splice
acceptor site (Wahl et al., 2009). In humans,∼92–94% of protein-
coding genes undergo cell or tissue-specific alternative splicing
(Wang et al., 2008). Cis-acting regulatory sequence elements
in the pre-mRNA can have positive or negative effects on the
selection of specific splice sites. The SR proteins bind to exonic
or intronic splicing enhancers or splicing silencers to stabilize
or weaken the spliceosomal complex and control the outcome
of splicing (for review see, Fu and Ares, 2014). They possess
one or two N-terminal RNA-recognition motifs (RRM) and a
C-terminal domain which is enriched in arginine and serine
dipeptides (RS domain). Binding of these proteins to the pre-
mRNA is mediated by their RRMs while the RS domain is used
for the recruitment of other splicing proteins to the spliceosome
via protein-protein interactions (Long and Caceres, 2009). Jmjd6
forms a trimeric complex with the U2AF65/U2AF35 heterodimer
and interacts with the SR proteins Luc7-like protein 2 (Luc7L2),
Luc7L3 (previously known as CROP), SRSF11, and Acinus S’
(Webby et al., 2009; Heim et al., 2014) which are involved in
different steps of exon definition and alternative splicing. Jmjd6
binds selectively to the RS domains of these proteins in preference
to other SR proteins (Heim et al., 2014). So far, Jmjd6-mediated
lysyl hydroxylation of K residues within RS domains has only
been shown for U2AF65 (endogenous protein) and Luc7L2
(peptide based) (Webby et al., 2009). There are several ways in
which Jmjd6 PTMs might influence splicing (Figure 5). U2AF65
is a subunit of the snRNP in the U2 spliceosome that binds to
the 3′ splice site of the pre-mRNA (Staknis and Reed, 1994)
while LUC7L2 and LUC7L3, similar to most other SR proteins,
are regulators involved in AS by modulating the recruitment
of snRNPs and by stabilizing the bonding between the U2AF
and the polypyrimidine tract (Puig et al., 2007; Bradley et al.,
2015). Hydroxylation of these SR proteins by Jmjd6 might control
the selection of exonic 3′-splice acceptor sites in the pre-mRNA
(Figure 5A). SR proteins that are hydroxylated by Jmjd6 at a local
exon site on the pre-mRNA might suppress the binding of U2
snRNP components at this position while allowing a preferential
interaction of unmodified SR proteins at a downstream splice
acceptor site within the spliceosome. The overall net outcome
of such a reaction would be the skipping of the upstream exon
in the processed mRNA (Figure 5B, hypothesis 1). Alternatively,
SR proteins that are hydroxylated by Jmjd6 might induce the
formation of different pre-mRNA structures. Secondary and
tertiary structures of RNA recruit splicing enhancers or silencers
to splice recognition sequences which are sometimes 100s or even
1000s of nucleotides apart on the primary transcript (Hiller et al.,
2007; Wan et al., 2014). For example, PY-tract-binding protein
(PTB) can bind to motifs in RNA and cause looping to repress
splicing in vivo (Lamichhane et al., 2010). The hydroxylation of
U2AF65 and other SR proteins by JMJD6 could possibly provide a
platform for pre-mRNA looping and the presentation of different
cis splice enhancer or silencer elements to the splicing machinery
(Figure 5B, hypotheses 2 and 3) (Shepard and Hertel, 2008; Fu
and Ares, 2014).
In some genes Pol II proximal promoter pause release is
associated with immediate downstream assembly of spliceosomal
components (David et al., 2011). In these systems, Jmjd6 could
regulate recruitment of SR and other components and thereby
co-regulate transcription and splicing (Figure 5B, hypothesis 4).
Future experiments can dissect underlying mechanisms using
RNA-protein UV crosslinking and immunoprecipitation (CLIP)
approaches coupled with high-throughput sequencing (CLIP-
seq, Konig et al., 2011; Cook et al., 2015) and chromatin
immunoprecipitation sequencing (ChIP-seq) of selected proteins
that constitute the transcriptional machinery. Whatever the
precise mechanism, Jmjd6 clearly modulates splicing in vivo,
mostly through direct interaction with its most validated
interaction partner U2AF65. For example, Jmjd6 regulates
in an oxygen-dependent manner the splicing of alternative
vascular endothelial cell growth factor receptor 1 transcripts
(VEGFR1, encoded by FLT1) (Boeckel et al., 2011). Reduced
Jmjd6 expression, either through knockout, or knockdown in
cells, correlated with increased expression of an alternative
splice variant of FLT1 that encodes a protein which lacks the
transmembrane and intracellular kinase domain of the normal
VEGF-receptor 1 (Boeckel et al., 2011). Jmjd6 was found to
mediate Flt1 splicing through interaction with U2AF65 which
was found to bind to Flt1 mRNA. Even in Jmjd6+/− mice, Flt1-
dependent angiogenic sprouting was suppressed in a matrigel
implant model in comparison to wild-type mice (Boeckel et al.,
2011). Jmjd6 appears to act downstream of TNFSF15, a negative
regulator vasculogenesis, which promotes expression of the
alternative sFlt-1 splice isoform through downregulation of
Jmjd6 expression (Qi et al., 2013).
A second example is the regulated splicing of the
ferrochelatase gene under iron limiting conditions (Barman-
Aksozen et al., 2013). Ferrochelatase catalyzes the terminal
step in the heme biosynthesis pathway. It inserts ferrous iron
into the heme precursor protoporphyrin IX to form heme B,
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FIGURE 5 | Functions of Jmjd6 in the regulation of splicing. (A) Possible role for JMJD6 in modulating binding of splicing regulatory proteins to splice
recognition sites on pre-mRNAs. JMJD6 forms a trimeric complex with U2AF65/U2AF35 and has been demonstrated to modulate splicing by lysyl hydroxylation of
U2AF65. JMJD6 interacts also with SR proteins that can bind to exon splicing enhancers (ESE) in proximity to 3′-splice acceptor sites. Examples of these SR
proteins are LUC7L1, LUC7L2, LUC7L3 (CROP), SRSF11, and Acinus S’ (Heim et al., 2014). JMJD6 mediated hydroxylation of SR proteins might influence selection
of exonic 3′-splice acceptor sites through stabilization or weakening of U2AF binding to polypyrimidine tracts. Shown are U1 snRNP binding to exonic 5′-splice
donor sites, binding of splicing factor 1 (SF1) and SR protein complexes to intronic branch point sequences (BPS), and assembly of the U2 spliceosome
components U2AF65 and U2AF35 together with JMJD6 and SR proteins at the polypyrimidine tract (Py-tract) and 3′-splice acceptor site. Examples of SR proteins
that interact with JMJD6 are depicted in the box on the left. (B) Hypotheses on mechanisms how JMJD6 could regulate mRNA splicing (see Functions of Jmjd6 in
RNA Processing – Regulation of Splicing). Hypothesis (1): Through JMJD6 mediated hydroxylation of SR proteins that bind to exonic splicing enhancers (ESE) exon
skipping may be induced. In this case, SR protein hydroxylation by JMJD6 at a local 3′-splice acceptor site might suppress assembly of U2 snRNP components
while preferential assembly of unmodified U2 splicing factors and SR proteins might occur at a 3′-splice acceptor site further downstream on the pre-mRNA.
Hypothesis (2): Hydroxylation of U2 snRNP components and SR proteins by JMJD6 may induce lopping of pre-mRNAs into different secondary or tertiary RNA
structures. JMJD6 mediated hydroxylation of SR proteins bound to exonic splicing silencers (ESS) may facilitate formation of pre-mRNA structures that inhibit
splicing of upstream exons. The pre-mRNA folding platform cannot assemble and neighboring exons are not brought into proximity to facilitate splicing. Hypothesis
(3): In this case JMJD6 mediated hydroxylation of U2 snRNP and SR proteins triggers the assembly of a platform at exonic splicing enhancers (ESE) that facilitates
pre-mRNA looping and recruitment of co-factors needed for exon inclusion into spliced mRNAs. Hypothesis (4): Involvement of JMJD6 in co-transcriptional
regulation of mRNA elongation and splicing. Hydroxylation of SR proteins by JMJD6 could regulate polymerase II (Pol II) transcriptional pause release and shuttling of
SR proteins from the transcription start complex into spliceosomal complexes where these then regulate splicing reactions.
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which is the oxygen carrier component in hemoglobin and an
essential co-factor in many proteins and enzymes (Dailey and
Meissner, 2013). Partial deficiency in ferrochelatase (FECH)
gene expression results in erythropoietic protophyria (EPP), an
inherited metabolic disorder. Under iron deficient conditions
aberrant splicing of a mutant FECH pre-mRNA variant leads
to reduced expression of the FECH protein (Barman-Aksozen
et al., 2013). The mutant FECH variant has a single nucleotide
polymorphism (IVS3-48C/T) immediately upstream of a weak
PY-tract in intron 3. The splicing factor U2AF65 binds to
a weak PY-tract 5′ to a constitutive splice site and catalyzes
the splicing of a predominantly correct transcript (Barman-
Aksozen et al., 2013). Under iron limiting conditions, when the
JMJD6-mediated U2AF65 lysyl-5-hydroxylation is inhibited,
the splice ratio is shifted and a stronger alternative PY-tract is
used which leads to inclusion of a partial intron 3-sequence
into the FECH mRNA (Barman-Aksozen et al., 2013). This
transcript variant encodes a premature termination codon
(PTC) and is subject to nonsense-mediated decay (NMD).
Patients, which carry the intron 3 SNP in trans to another
deleterious FECH allele, are at a particular risk to develop
EPP disease. Mechanistically differential binding of U2AF65
to weak or strong PY-tracts is proposed to be regulated by
JMJD6. As a Fe2+-dependent dioxygenase Jmjd6 is suggested
to lysyl hydroxylate U2AF65 at a critical residue (K276) within
its second RRM motif which affects the strength of U2AF65
binding to PY-tracts and selection of 3′-splice acceptor sites.
Such a regulative function of alternative splicing has been long
recognized for a number of other genes (Lewis et al., 2003). In
cases where protein expression needs to be regulated tightly,
alternative splicing often produces transcripts that differentially
undergo NMD. Alternative splice events that target transcripts
for NMD to quantitatively regulate gene expression have
been termed AS-NMD (alternative-splicing-coupled NMD)
or alternatively RUST (regulated unproductive splicing and
translation). Interestingly, many splicing regulatory proteins
including factors of the core splicing machinery and SR proteins
have been reported to autoregulate their own expression through
AS-NMD (for review see, Sibley, 2014). This mechanism has
been suggested to be important for tissue-specific regulation
of splicing patterns and gene expression adaptation to external
cues (Boutz et al., 2007). Through its interactions with SR-
proteins and their PTM, JMJD6 could have a role in regulating
AS-NMD events. The enzymatic activity of Jmjd6 is not only
regulated by iron but also by oxygen levels and the availability
of its other enzymatic co-factor 2OG (Webby et al., 2009;
Boeckel et al., 2011). Moreover, other tricarboxylic acid cycle
intermediates such as fumarate and succinate are known to
inhibit the enzymatic activity of 2OG dependent dioxygenases
(Salminen et al., 2014; Ploumakis and Coleman, 2015). The
examples of Jmjd6 regulated splicing of AIRE, FLT1, and FECH,
which all involve mechanisms of intron retention and usage of
PTCs leading either to mRNAs subjected to NMD or expression
of truncated proteins, suggest that Jmjd6 might have a wider
significance in regulating alternative splicing of transcripts that
contain PTCs.
EMERGING ROLES OF Jmjd6 IN
CANCER
Many published studies link high expression of JMJD6 with
severe pathological tumor grades, increased tumor growth and/or
metastasis (Lee et al., 2012; Zhang et al., 2013; Wang et al.,
2014; Poulard et al., 2015; Aprelikova et al., 2016). One candidate
mechanism is based upon interaction of JMJD6 and the p53
tumor-suppressor protein pathway (Wang et al., 2014). In
colon carcinoma HCT116 cells, p53 was bound by JMJD6 and
hydroxylated at lysine 382 (p53K382) in its C-terminal domain.
The specificity of the JMJD6 catalyzed reaction was demonstrated
in vitro with recombinant JMJD6 and p53 and in vivo on
endogenous p53 purified from HCT116 cells by employing
LC–MS/MS analyses (Wang et al., 2014). An inactive JMJD6
mutant did not hydroxylate p53 and absence of Fe2+ and
2OG from reactions also abolished the p53K382 hydroxylation.
Hydroxylation of p53K382 was shown to antagonize CBP/p300-
mediated acetylation at the same residue. Cells depleted of JMJD6
by siRNA showed reduced levels of p53K382ac in immunoblots
and reduced binding of p53 to the promoters of its target genes
P21 and PUMA (Wang et al., 2014). Acetylation of p53 by
CBP/p300 at five lysine residues in its C-terminal regulatory
domain has been well-documented to fine tune p53 functions
(for review see, Reed and Quelle, 2014). Depending on the
particular C-terminal lysine modified, acetylation can modulate
the p53 DNA binding affinity and/or co-recruitment of other
transcription factors (Figure 6A). However, the importance of
p53 acetylation on its canonical functions of cell cycle arrest,
cell senescence and programmed cell death (apoptosis) are less
clear (Reed and Quelle, 2014). HCT116 cells treated with JMJD6
siRNAs were more prone to apoptosis upon challenge with the
DNA damaging agent VP16, and showed altered growth in
xenotransplantation in nude mice, dependent on the presence
of p53. These data together suggest that hydroxylation catalyzed
by JMJD6 inhibits the tumor suppressor function of p53 (Wang
et al., 2014) (Figure 6A).
JMJD6’s contribution to control of apoptosis has also
described in mouse mammary tumor models that mimic
human breast cancer. A commonly amplified chromosomal
region on distal mouse chromosome 11 in tumor samples
of three mouse cancer models encompasses the Jmjd6 gene.
This region is syntenic to human chromosome 17q23-qter,
which is commonly amplified in human breast cancer patients
(Aprelikova et al., 2016). In one model studied in detail, Jmjd6
was expressed at higher levels in MMTV-Myc transgene derived
cell lines compared to controls, probably due to a copy number
gain (Aprelikova et al., 2016). c-Myc is a proto-oncogene
which can induce cellular proliferation and has pro-apoptotic
functions in normal cells experiencing stress (Hoffman and
Liebermann, 2008) by inducing expression of the murine p19ARF
protein (also known as cyclin-dependent kinase inhibitor 2A;
CDKNA2/p14ARF in humans) which binds to the MDM2
E3 ubiquitin ligase that regulates p53 stability (Rizos et al.,
2007; Hoffman and Liebermann, 2008) (Figure 6B). Jmjd6
overexpression in MMTV-Myc driven tumor cell lines reduces
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FIGURE 6 | Roles of Jmjd6 in cancer. (A) JMJD6 regulates P53 functions by hydroxylation. Inactive P53 is normally locked in a closed confirmation which
prevents its binding to target genes on genomic DNA. Acetylation by different acetyltransferases such as p300/CBP (blue) and the p300-CBP associated factor
(PCAF, yellow) at C-terminal located lysines (K370-K382) affects P53 transcriptional activity by opening up its closed confirmation exposing its central DNA binding
domain. Binding of P53 to gene promoters and recruitment of co-factors induces expression of target genes such as P21 and PUMA. Lysyl hydroxylation of P53K382
by JMJD6 has been described to suppress expression of P21 and PUMA by preventing P53 acetylation at this amino acid (Wang et al., 2014). (B) Hypothesis of
how amplification of Jmjd6 in mouse mammary tumor models inhibits c-Myc induced apoptosis and enhances tumorigenesis. In normal cells (top row) where c-Myc
(green) is not mutated, the E3 ubiquitin-protein ligase Mdm2 (Mouse double minute 2 homolog, purple) ubiquitinates p53 thereby leading to its proteosomal
degradation. In cancer cells (middle row), upregulated expression of mutated c-Myc induces Cdkna2 (cyclin-dependent kinase inhibitor 2A, also known as
p19/14ARF, blue) expression. Cdkna2 binds to Mdm2 and antagonizes its ubiquitin ligase function thereby leading to stabilization of p53. Upregulated p53 induces
several important cellular processes linked to tumor suppression (indicated by arrows on the left) foremost induction of apoptosis. In advanced MMTV-Myc induced
tumors, the Jmjd6 gene copy number is amplified leading to elevated levels of Jmjd6 protein (red) expression (bottom row). Through its histone arginine
demethylation activity, Jmjd6 demethylates the activating histone mark H4R3me2a at the Cdkn2a promoter leading to diminished expression of this Mdm2 inhibitor.
P53 is subjected to proteosomal degradation leading consequently to a loss of its tumor suppression function. According to the model of Aprelikova et al. (2016)
amplified Jmjd6 has pro-oncogenic functions through interference with p53 functions and elevated JMJD6 expression in tumor tissue is therefore an unfavorable
prognostic marker for cancer prognosis.
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expression of p19ARF, possibly by demethylating an activating
H4R3me2a histone mark at the Cdkna2 promoter leading to
reduced p53 expression and increased tumorigenic activity
(Aprelikova et al., 2016). This mechanism may or may not
also be related to the JMJD6-p53 hydroxylation activity (Wang
et al., 2014). Interestingly, Jmjd6 overexpressing tumors also
showed reduced amounts of apoptotic cells, thus supporting the
argument that Jmjd6 might suppress c-Myc-induced apoptosis.
However, at this stage it still needs to be established whether
amplification of Jmjd6 and c-Myc driven initiation or progression
of tumorigenesis might be a more general mechanism across
different types of cancers.
Jmjd6 may also intersect with estrogen receptor signaling in
breast cancer, through regulated methylation of the estrogen
receptor α (ERα). Methylation of ERα at R260 is critical for the
interaction of the receptor with the Src and PI3K kinases and
activation of the Akt pathway. Demethylation of ERα by JMJD6
could therefore negatively regulate responses of breast cancer
cells to estrogen. Demethylation of ERα by JMJD6 was shown
in vitro using an anti-ERαR260me2a antibody and recombinant
JMJD6 protein (Poulard et al., 2014). A low efficiency of the assay
reaction suggested that additional co-factors may be needed that
either support the binding of JMJD6 to its substrate or increase
its enzymatic activity (Poulard et al., 2016).
Although several studies have suggested a role for Jmjd6 in
tumorigenesis, the primary pathways and targets of Jmjd6 that
might promote development or progression of cancer are not
clear. For example, different studies have reported pro- or anti-
proliferative functions of JMJD6 in human MCF-7 breast cancer
cell lines (Lee et al., 2012; Poulard et al., 2015). The enzymatic
activity of Jmjd6 is likely to be inhibited under oxygen limiting
conditions (Webby et al., 2009; Boeckel et al., 2011). This might
have implications for the described JMJD6 p53 hydroxylation
activity in hypoxic tumor tissue. Several different types of cancer
are known to have widespread alterations in alternative splicing
either globally or in specific genes. Some of these splicing defects
have been linked to occurrence of somatic mutations in genes
encoding core spliceosome components or associated splicing
factors. Mutations in U2AF1, U2AF2, SF3B1 and SRSF2 occur
frequently in myelodysplastic syndromes and different types of
leukemia (for review see, Dvinge et al., 2016; Scotti and Swanson,
2016). The cBioPortal and COSMIC database1 of sequenced
cancer genomes shows JMJD6 mutation frequencies of up to
24% in 62 from 126 of the available Cancer Genome Atlas
(TCGA) studies (Cerami et al., 2012; Gao et al., 2013). The
highest mutation load (20–24%) is detected in xenograft clones
from breast cancer patients and neuroendocrine prostate cancer
samples. The majority of detected JMJD6 alterations are gain-
of-copy number mutations (amplifications). Others included
deletions and point mutations that are distributed more or less
equally over the whole JMJD6 locus (Supplementary Figure S2).
There is no mutation enrichment in regions encoding the JMJD6
catalytic center or in particular cancer types with the exception of
the aforementioned breast cancer and neuroendocrine prostate
cancer samples (Supplementary Figure S2). If any of these
1http://www.cbioportal.org/
have functional relevance as true driver events for initiation
or progression of cancer needs to be tested. Functional links
between Jmjd6 and breast cancer are particularly interesting as
deregulation of splicing factors and defects in the crosstalk of the
splicing network have been proposed to contribute toward cancer
development (Silipo et al., 2015).
EMERGING FUNCTIONS OF Jmjd6 IN
INFECTION, INFLAMMATION, AND
IMMUNE RESPONSES
Studies of Jmjd6 mice indicated a necessary function in thymus
and T cell development, probably through the regulation of Aire
as discussed above (Kunisaki et al., 2004; Yanagihara et al., 2015).
In patients with chronic infections, T cell-mediated immunity
can become “exhausted.” In patients with chronic hepatitis B
virus infection JMJD6 expression was reduced in T lymphocytes
(Chen et al., 2014). Silencing of JMJD6 expression in normal
peripheral blood mononuclear cells selectively suppressed the
proliferation of CD4+ T cells and apparently elevated expression
levels of the cycle associated gene, cyclin-dependent kinase
inhibitor 3 (CDKN3) (Chen et al., 2014), a known inhibitor
of cell cycle progression (Gyuris et al., 1993). The impaired T
cell proliferation, and decreased JMJD6 in hepatitis patients was
linked in turn, via in vitro assays, to elevated circulating platelet-
derived growth factor (PDGF-BB) (Chen et al., 2014). However, it
is unclear whether the roles of JMJD6 in T cell exhaustion are cell
autonomous, and the FANTOM5 data suggests that in humans
at least, JMJD6 is much more highly expressed in candidate
antigen-presenting cells.
Given its roles in RNA metabolism, and expression in immune
cells, Jmjd6 is likely to be required for several aspects of viral
RNA replication cycles. Direct evidence of a pro-viral role
came from studies of the replication of foot-and-mouth disease
virus (FMDV) (Lawrence et al., 2014). FMDV replicates in the
cytoplasm and requires host RNA helicase A (DHX9) which
interacts with the viral genome and supports its replication
(Lawrence and Rieder, 2009). In uninfected cells DHX9 is pre-
dominantly located in the nucleus where it is involved in splicing
and RNA processing by binding to heterogeneous nuclear
ribonucleoproteins. FMDV infection triggers the shuttling of
DHX9 from the nucleus to the cytoplasm where it accumulates
3–4 h post-infection (Lawrence and Rieder, 2009). The nuclear-
cytoplasmic shuttling of DHX9 is determined by a PTM
which involves demethylation of arginine-glycine-glycine (RGG)
repeats in its C-terminal nuclear transport domain region
(Lawrence and Rieder, 2009). Reciprocal immunoprecipitation
confirmed a physical interaction and recombinant JMJD6 was
found to demethylate FLAG-tagged and affinity purified DHX9
(Lawrence et al., 2014). Demethylation requires the presence of
Fe2+ and 2OG, and was inhibited with N-oxalylglycine (NOG), a
general inhibitor of 2OG-dependent JmjC dioxygenases. Formal
proof of the importance of this process still requires analysis of
JMJD6-deficient cells and cross-validation of the demethylation
with LC–MS/MS based analyses on endogenous DHX9 protein
(Lawrence et al., 2014).
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Within innate immune cells, where Jmjd6 is most highly
expressed, one candidate target of arginine demethylase activity
is Tumor Necrosis Factor Receptor-associated Factor 6 (TRAF6).
TRAF6 is a non-conventional E3 ubiquitin ligase that acts
downstream of several important immune pathways including
the tumor necrosis factor receptor (TNFR) superfamily, the
T cell receptor (TCR), the interleukin 1 receptor (IL1R), and
the toll-like receptor (TLR) pathways (Walsh et al., 2015).
TRAF6 is reversibly methylated and demethylated at 12 different
arginine sites along the protein (Tikhanovich et al., 2015).
Methylation of TRAF6 by PRMT1 was shown to inhibit its
ubiquitin ligase activity and to suppress the activation of NF-κB
target genes. The authors hypothesized that PRMT1 methylation
of TRAF6 occurs in naïve cells that are not activated by
TLR ligands. This raised the question of whether TRAF6 is
demethylated upon TLR activation. Co-immunoprecipitation
experiments revealed an interaction between JMJD6 and TRAF6,
and overexpression of JMJD6 reduced TRAF6 methylation and
ubiquitination in human Huh 7.5 hepatocarcinoma cells which
resulted in enhanced NF-κB activation (Tikhanovich et al.,
2015). Analysis of TRAF6 methylation kinetics upon stimulation
with two different TLR ligands, FSL-1 (TLR6/2 agonist) and
lipopolysaccharide (LPS/TLR4 agonist), showed that negative
regulation of TRAF6 by arginine methylation is dependent on
PRMT1. 30 min after LPS and FSL-1 treatment, PRMT1 protein
levels were drastically reduced while JMJD6 expression levels
remain constant. Thus, TLR-ligand induced demethylation of
TRAF6 seems to be regulated by loss of PRMT1 expression rather
than by JMJD6 catalytic activity. Knockdown of JMJD6 decreased
NF-κB activation in response to TLR ligands but had no effect
on basal pathway activation. This suggested that TRAF6 activity
is dependent on the relative abundance of PRMT1 and JMJD6
rather than on the amount or activity of either enzyme alone.
The TRAF6 residues R88 and R125 seem to be critical for the
negative regulation of TLR signaling by demethylation. However,
the question of these residues being direct targets of JMJD6
demethylation still needs to be demonstrated using quantitative
LC–MS/MS analyses.
CONCLUDING REMARKS AND FUTURE
PERSPECTIVES
Validating and characterizing Jmjd6 reactions in vitro has been
a very difficult task. Most analyses have used recombinant or
cell purified, tagged Jmjd6 with candidate substrates and its co-
factors 2OG and Fe2+ in isolation (see Supplementary Table S1).
In contrast to other members of the JmjC protein family, Jmjd6
has no other accessory domains such as plant homeodomain
(PHD) zinc finger domains, AT-rich interacting domains, other
types of zinc finger domains or TUDOR domains that control for
example substrate specificities of larger histone KDMs (Kooistra
and Helin, 2012). It is very likely that Jmjd6 interacting proteins
or co-factors are needed to make Jmjd6 reactions in vitro more
efficient for MS based quantification of reaction products. Here,
the whole field has been hampered for more than a decade by
the unavailability of specific and well-characterized anti-Jmjd6
antibodies that can be used for co-immunoprecipitation assays
or enrichment of Jmjd6 interaction partners and substrates. One
way forward is the possibility of insertion of specific small epitope
tags into endogenous genomic loci using CRISPR-Cas9-mediated
homology-directed repair (Mikuni et al., 2016; Wang and Qi,
2016). A tagged Jmjd6 allele that retains all of its activities and
regulation would be a valuable resource. It could be used to
experimentally dissect the Jmjd6 substrate repertoire in a given
physiological condition or cell type of interest by combining
small epitope allele tagging with unbiased proteome assessments
in vivo (Singh et al., 2015). Making full use of such genetic tools
could help to answer questions about the biological importance
of multiple Jmjd6-substrate interactions and to gain access to the
associated down-stream signaling events and to the mechanisms
that control them. Jmjd6 is not unique amongst the JmjC protein
family in the diversity of its potential substrates. For example, the
ribosomal oxygenases RIOX1 (NO66) and RIOX2 (also known
as Mina53) catalyze hydroxylation of histidinyl residues in the
60S ribosomal subunit proteins L8 (Rpl8) and L27a (Rpl27a),
respectively (Ge et al., 2012) but also appear to function as histone
demethylases for the histone marks H3K4me1 and H3K36me1
(RIOX1, Sinha et al., 2010) and H3K9me3 (RIOX2, Lu et al.,
2009). Which are the most important physiological substrates for
a 2OG-dependent dioxygenase in a particular condition in vivo?
Are their functions redundant, or required only to fine-tune
other downstream processes such as gene transcription, mRNA
splicing, or protein translation? Answers to these questions
can only be revealed when appropriate in vivo systems for
experimental analysis are established which allow the assessment
of multiple potential substrates simultaneously. Similarly, the
conditional knockout allele of Jmjd6 will be crucial for the
assignment of spatiotemporal Jmjd6 functions and their roles
in animal models of disease that cover areas such as cancer,
inflammation and infection.
There remain many questions about structure–function
relationships for Jmjd6. For example, how does Jmjd6 bind to
RNA? Which motifs and regions of the protein are needed for
RNA interactions and which different classes of RNA molecules
are targets of the protein? Is Jmjd6 regulated by PTMs such
as sumoylation and phosphorylation and how does its own
auto-hydroxylation activity regulate Jmjd6 oligomerization? The
detailed understanding of Jmjd6 substrate interactions requires
the structural elucidation of Jmjd6/substrate co-complexes. Such
analyses could tell how different substrates can be accommodated
in the Jmjd6 catalytic cleft. The catalytic site might be relatively
accessible and an extended flexible loop terminal to the first
β-strand of its DSBH can be also found in some KDMs providing
support for the demethylation activity of the protein (Markolovic
et al., 2016).
Recently, a subset of KDMs was discovered, including
KDM3A, KDM4E, KDM5C and KDM6B, that can catalyze
demethylation of methylated arginines in both histone and
non-histone substrates in vitro (Walport et al., 2016). This
again raises questions about both context specific enzyme
activities and functional redundancies in vivo. One reason why
Jmjd6 is so indiscriminate in targeting so many substrates
might lie in its role in carrying out oxygenase functions
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in large and dynamic ribonucleoprotein (RNP) machineries.
Arginine methylation of RNA-binding proteins in RNPs such as
transcription initiation complexes, spliceosome and ribosomes
is well-established and known to regulate diverse cell and
tissue differentiation functions (for review see, Blackwell and
Ceman, 2012). Jmjd6, itself an RNA-binding protein, has been
established in several independent studies to interact with
multiple RNA-binding proteins as summarized above. In some
cases, interactions of Jmjd6 with multiple partners in larger
complexes might be determined by its interaction with RNA
rather than by direct protein-protein contacts. RNase treatment
experiments and co-immunoprecipitation studies have shown
that the nuclear localization of Jmjd6 and its interaction with
particular SR-proteins can be RNA-dependent (Hahn et al., 2008;
Heim et al., 2014). Thus, pull-down studies might precipitate
larger complexes of Jmjd6 and other proteins that are tightly
held together by structural or transcribed RNAs. With the
development and further refinement of mass spectrometry
methods that reliably use affinity or chemical enrichment
of arginine methylated proteins, a more comprehensive and
quantitative evaluation of arginine methylomes, in the context of
RNA metabolism and RNA processing, might be accomplished
(Larsen et al., 2016). Future work in this direction should be
guided by genetic analyses which combine in vivo studies on
biochemical and cellular mechanisms of Jmjd6 in a physiological
context.
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FIGURE S1 | Tissue expression of human and murine JMJD6/Jmjd6 in
BioGPS (biogps.org). (Left) Expression of JMJD6 in 79 human tissues based on
the Affymetrix GeneAtlas U133A dataset. (Right) Expression of murine Jmjd6 in
61 mouse tissues based on the GeneAtlas MOE430 dataset. Cells and tissues
with related ontology are shown in similar colors.
FIGURE S2 | JMJD6 mutation frequencies as shown in the cBioPortal
(http://www.cbioportal.org) of the human Cancer Genome Atlas (TCGA).
The majority of detected JMJD6 alterations are gain-of-copy number mutations.
Green color in columns indicate frequency of SNP mutations, blue color deletions,
red color amplifications, and gray color multiple gene alterations. Cancer types
from different cancer genome studies are shown at the bottom of the graph.
TABLE S1 | Identified Jmjd6 interaction partners and substrates. It shows
protein and RNA substrates that have been described to be post-translationally
modified by Jmjd6. Methods and substrates used in the detection of
post-translational modifications (PTMs) are listed. Where endogenous Jmjd6
substrates have been validated, used in vivo methods are indicated.
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